Sitafloxacin is a 4th generation fluoroquinolone antibiotic with broad activity against a wide range of Gram-negative and Gram-positive bacteria. It is approved in Japan and used to treat pneumonia and urinary tract infections (UTIs) as well as other upper and lower respiratory infections, genitourinary infections, oral infections and otitis media.

Sitafloxacin is a new generation fluoroquinolone that exhibits excellent in vitro activity against many Gram-positive, Gram-negative, anaerobic bacteria, and atypical pathogens. Moreover, it remains active against the strains resistant to other fluoroquinolones [ 1 ].

2017年6月23日 · Sitafloxacin is a fluoroquinolone antibiotic indicated in the treatment of susceptible bacterial infections.

2011年4月16日 · Sitafloxacin is a fluoroquinolone antibacterial with in vitro activity against a broad range of Gram-positive and -negative bacteria, including anaerobic bacteria, as well as against atypical pathogens.

Oral sitafloxacin demonstrated high rates of clinical success in the treatment of acute complicated UTI and pyelonephritis. Overall tolerability profile of sitafloxacin is favorable. Complicated urinary tract infections and acute pyelonephritis are relatively common infectious genitourinary problems.

2020年3月2日 · To provide better evidence of the efficacy and safety of sitafloxacin on treating acute bacterial infections, we conducted this comprehensive and updated meta-analysis. 2. Methods. 2.1. Study Search and Selection.

2012年11月18日 · Sitafloxacin is a fluoroquinolone antibacterial with in vitro activity against a broad range of Grampositive and -negative bacteria, including anaerobic bacteria, as well as against atypical pathogens.

Sitafloxacin is a member of quinolines, a quinolone antibiotic and a fluoroquinolone antibiotic. SITAFLOXACIN ANHYDROUS is a small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.

2020年6月8日 · We present early data on combination therapy with doxycycline and sitafloxacin to treat highly resistant M. genitalium. We found the regimen was well tolerated and cured 11/12 infections that had failed prior regimens with moxifloxacin and pristinamycin.

2024年11月16日 · Sitafloxacin is a 4th generation fluoroquinolone antibiotic with broad activity against a wide range of Gram-negative and Gram-positive bacteria. It is approved in Japan and used to treat pneumonia and urinary tract infections (UTIs) as well as other upper and lower respiratory infections, genitourinary infections, oral infections and otitis media.